Literature DB >> 7105823

Pharmacokinetics of oral indoramin.

G N Volans, D Jeffereys, A N Latham, T Frost.   

Abstract

A randomized crossover study was carried out in 7 healthy subjects to investigate the pharmacokinetics of indoramin from two oral formulations (film-coated and uncoated 50 mg tablets) and to determine the effect of a standard mean on the plasma concentration time curve of the film-coated form. The results indicated that peak plasma concentrations occurred in 1 to 4 hours after treatment with a single dose of 2 tablets, with an overall elimination half-life of 5 hours. No significant differences could be shown between treatments in any of the pharmacokinetic variables determined. However, administration of film-coated indoramin after a standard meal narrowed the range of peak concentrations but the time at which peak concentrations of the drug occurred did not appear to be related to whether or not indoramin was given after the meal.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7105823     DOI: 10.1185/03007998209109757

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.

Authors:  D M Pierce; S E Smith; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.

Authors:  H M Norbury; R A Franklin; P K Marrott; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

6.  Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers.

Authors:  H M Norbury; R A Franklin; P K Marrott; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.